Funded with Support from

The FDA has expanded the indication for Omidria, a mydriatic and NSAID combination agent, to include use in pediatric patients from birth through 17 years.

A 23-year-old woman presents for a "metabolic evaluation."

Using data from the Infant Aphakia Treatment Study (IATS), investigators assessed the prevalence of anisometropia among children who were randomized to IOL implantation as infants.

In this webinar presentation from AAPOS, Drs.Lambert, Wilson, Plager, and Lloyd present an update on the management of pediatric cataracts.

Researchers from China have developed an artificial intelligence (AI) platform that can diagnose congenital cataracts as accurately as ophthalmologists.

In this webinar presentation from Orbis, Dr. Dan Neely discusses the technical considerations of pediatric cataract, including management of the anterior and posterior capsule, removal of lens material, and IOLs.

Weekly case challenge

In children, cataract causes more visual disability than any other form of treatable blindness. Children with untreated, visually significant cataracts face a lifetime of blindness at tremendous quality of life and socioeconomic costs to the child, the family, and the society. More than 200,000 children are blind from unoperated cataract, from complications of cataract surgery, or from ocular anomalies associated with cataracts.

Dr. Rosenthal discusses the history of this unique IOL design and its advantages in a pediatric population.